Form 4: Agios Pharmaceuticals' Chief Legal Officer, James William Burns, Reports Recent Stock Transactions

James William Burns, Chief Legal Officer of Agios Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, in recent transactions.

Summary

• James William Burns, the Chief Legal Officer of Agios Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2024, Burns acquired 3,834 shares of common stock through the company's employee stock purchase plan and 4,000 restricted stock units.
• Also on March 1, 2024, Burns was granted 17,000 restricted stock units and options to purchase 60,000 shares.
• On March 5, 2024, Burns sold 1,293 shares at $32.57 and 1,349 shares at $32.57 to cover tax withholding obligations related to vesting performance share units.
• Following these transactions, Burns directly owns 37,169 shares of Agios Pharmaceuticals common stock and various derivative securities.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports transactions. The grants are positive, but the sales are neutral as they are for tax purposes.

Positives

• The acquisition of shares through the employee stock purchase plan indicates confidence in the company.
• The grant of restricted stock units and stock options aligns the executive's interests with the long-term performance of the company.

Negatives

• The sale of shares to cover tax obligations, while routine, slightly reduces the executive's holdings.

Future Outlook

The document outlines future vesting schedules for restricted stock units and stock options, indicating a long-term incentive structure for the reporting person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry, used to align management incentives with shareholder value.
• Vesting schedules of three to four years are typical for such grants, similar to practices at companies like Vertex Pharmaceuticals and Regeneron.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely to be minimal.

Key Dates